ABOUT ANTICANCER, INC.

History:

• Founded in 1984.
• Oldest free-standing Biotechnology Company in the San Diego cluster.

Employees:

35 including 20 PhDs and MDs. [CLICK HERE FOR THE PHOTO OF COMPANY EMPLOYEES]

Products:

TOOLS

Oncobrite^â

• The leading small-animal imaging Technology
• OncoBrite^â Imaging Technology is based on green fluorescent protein (GFP) and related fluorescent proteins.
• OncoBrite^â can image tumor growth, metastasis, angiogenesis, tumor cell trafficking, gene expression and other in vivo processes in real time.
• The leading technology for real-time drug discovery.
• More than one hundred cancer cell lines engineered with fluorescent proteins.
• The Olympus OV100 Whole Mouse Imaging system is designed for OncoBrite^â Technology.
• See Publications list (PDF Library)
• Contact Li Tang, Business Development Manager, for licensing, contract research and equipment: all@anticancer.com
• OncoBrite^â patents:

US: 6,232,523; 6,759,038; 6,235,968; 6,251,384; 6,649,159; 6,905,831

Australia: 749,338

Numerous worldwide patents pending

MetaMouse^â- ANGIOMOUSE^â

• The leading mouse models of human cancer.
• Patient-like mouse models of human metastatic cancer and angiogenesis.
• Models of all cancer types.
• The only patient-like models for metastasis and angiogenesis drug discovery.
• Technology uses surgical orthotopic implantation (SOI) of human cancer cell lines and patient tumors.
• Tumor growth and metastasis in MetaMouse^â - AngioMouse^â mimics clinical cancer.
• More than one hundred MetaMouse^â- AngioMouse^â- OncoBrite^â imageable mouse models are available.
• See Publication list (PDF Library)
• Contact Li Tang, Business Development Manager, for licensing and contract research.
• MetaMouse^â patents:

US: 5,491,284; 5,569,812

Japan: 2,664,261

Europe: 0437488

HDRA^â

· Histoculture Drug Response Assay

· Individualized Cancer Therapy

· In vitro drug sensitivity and resistance for solid tumors specimens from all patients for optimal drug treatment

· HDRA results correlate with patient survival

· See publication list (PDF Library)

· Contact Li Tang, Business Development Manager, for cancer patient testing and drug discovery screening: all@anticancer.com

· HDRA^â Patents:

US: 5,424,909; 5,726,009;

Europe: 714,448

THERAPEUTICS

Oncase-PEG^â

• PEGylated recombinant methioninase (PEG-rMETase)
• Recombinant protein depletes methionine in tumors
• Tumor growth arrested and drug sensitivity induced
• Active against all cancer types
• IND filing in preparation
• See publication list (PDF Library)
• Contact Li Tang, Business Development Manager, for ONCase-PEG^â licensing opportunities: all@anticancer.com
• ONCase-PEG^â Patents:

US:6,231,854; 6,461,851; 5,888,506; 5,690,929; 5,891,704; 5,715,835; 5;861,154; 5,863,788;

Japan: 2,930,723

Europe: 668,933; 839,055

Australia: 687,768; 708,361; 752,107

China: ZL96190574.3

STEM CELLS

• Pluripotent hair follicle stem cells for general regenerative medicine
• Hair follicle stem cells for nerve regeneration
• See Publication list (PDF Library)
• Hair follicle stem cell therapeutic patents:

US and worldwide patents pending

• Contact Li Tang, Business Development Manager, for hair follicle stem cells therapeutic licensing: all@anticancer.com

TUMOR-TARGETING BACTERIA

• Salmonella typhimurium A1 auxotroph targets prostate and breast cancer
• Additional Salmonella typhimurium auxotrophs are being developed to target other tumor types
• See publication list (PDF Library)
• Contact Li Tang, Business Development Manager, for licensing: all@anticancer.com
• Tumor-targeting bacteria patents:

US and worldwide patents pending

DRUG DELIVERY

DERMATEK^â

· Liposome-based hair-follicle targeting Technology

· Small and large molecules can be targeted to the hair follicle

· Hair follicle gene therapy

· 3-D culture of full thickness skin for hair growth stimulator and pigment modifier discovery

· See publication list (PDF Library)

· Contact Li Tang, Business Development Manager, for DermaTek^â licensing and contract research: all@anticancer.com

· DermaTek^â Patents:

US: 5,965,157; 5,646,508; 5,965,157; 6,224,901; 6,733,776; 5,914,126; 5,753,263.

Japan: 2,950,520

Europe: 692,972

Canada: 2,159,626

DIAGNOSTICS

A/C Diagnostics, LLC

• AntiCancer Subsidiary

· Enzymatic Homocysteine Assay

· The simplest, least expensive homocysteine assay

· 510 (k) cleared

· Automated on Hitachi 912 and related instruments

· Portable assay with 2 kg portable fluorescence reader

· Enzymatic Homocysteine Assay Patents:

US: 6,140,102; 5,985,540; 5,998,191; 6,066,467; 6,468,762; 6,448,446

Japan: 3,337,693

Europe: 1,265,846

· Enzymatic B₆ assay

· Only non-radioactive enzymatic assay for B6

· Microtiter plate format

· Automated with TECAN FREEDOM EVO

· Enzymatic B₆ Assay Patents:

US: 6,426,194

Worldwide patents pending

· Enzymatic cysteine assay

· Simple enzymatic assay for cysteine

· Suitable for automation on numerous platforms

· See publication list (PDF Library) for all A/C Diagnostics Publications

· Contact Li Tang, Business Development Manager, for all A/C Diagnostics products: all@anticancer.com

· Enzymatic Cysteine Assay Patents:

US: patent allowed;

Worldwide patents pending